December 3, 2025 AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer’s disease
October 14, 2025 Response letter to previous article published about Alzstatin’s unique mode of action against Alzheimer’s
September 8, 2025 Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025
September 4, 2025 Data from AlzeCure’s pain project ACD440 presented at the NeuPSIG 2025 pain conference
August 19, 2025 AlzeCure Pharma livestreams event about the pain project ACD440 and the opportunities within orphan drugs
August 5, 2025 New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference
July 29, 2025 New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain
June 12, 2025 AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease
April 7, 2025 New data bolstering the anti-inflammatory effect of NeuroRestore ACD856 presented at Alzheimer’s conference
April 2, 2025 New scientific article in Nature linking the potential use of NeuroRestore ACD856 for the treament of obesity
February 24, 2025 New article showing the unique mechanism of action behind Alzstatin as an Alzheimer’s treatment
February 17, 2025 AlzeCure receives EU grant for Phase 2 clinical trial of NeuroRestore ACD856 for Alzheimer’s disease
January 21, 2025 AlzeCure receives abstract acceptance at Alzheimer’s congress AD/PD 2025 on NeuroRestore ACD856
October 30, 2024 AlzeCure presents new anti-inflammatory data with NeuroRestore ACD856 at the Alzheimer’s conference CTAD
October 28, 2024 AlzeCure presents new positive data for the TrkA-NAM pain project against osteoarthritis
October 24, 2024 AlzeCure to present at the international partnering conference Bioscience 2024 on November 7
October 10, 2024 AlzeCure Pharma broadcasts live event about the phase II candidate ACD440 against neuropathic pain
October 1, 2024 AlzeCure’s abstract on ACD856’s anti-inflammatory effects to be presented at a leading Alzheimer’s conference
August 13, 2024 New scientific article on NeuroRestore ACD856 and its improved cognition and disease modification of Alzheimer’s disease
August 7, 2024 New results from AlzeCure’s pain project TrkA-NAM presented at the pain conference IASP 2024
June 13, 2024 New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain
May 15, 2024 Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member
May 13, 2024 AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer’s leading to new patent application
April 25, 2024 The extraordinary general meeting of AlzeCure Pharma AB approved the decision on the new issue of shares
April 10, 2024 Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board
March 7, 2024 AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference
March 5, 2024 AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer’s
February 12, 2024 AlzeCure Pharma broadcasts live expert event on Alzheimer’s around highly current gamma-secretase modulators
February 6, 2024 AlzeCure gets Late Breaking abstract of new preclinical data with ACD856 accepted at AD/PD 2024 conference
January 31, 2024 AlzeCure CEO Martin Jönsson to present at the international investor conference BioCapitalEurope
January 29, 2024 AlzeCure selects drug candidate and enters next phase of development with TrkA-NAM ACD137 against severe pain
January 17, 2024 The government draws attention to Swedish Alzheimer’s research and together with the Swedish Alzheimer’s Foundation visit AlzeCure Pharma
November 28, 2023 AlzeCure presents at DNB Nordic-American Healthcare Conference in New York December 6-7
October 25, 2023 AlzeCure presents disease-modifying data with NeuroRestore ACD856 at Alzheimer’s conference CTAD
October 17, 2023 AlzeCure publishes new article on the GSM mechanism behind Alzstatin against Alzheimer’s disease
October 12, 2023 AlzeCure presents clinical phase II-data with ACD440 for neuropathic pain at pain conference
September 26, 2023 AlzeCure gets presentation accepted on disease-modifying effects of ACD856 at Alzheimer’s conference
September 20, 2023 AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
September 18, 2023 AlzeCure gets an abstract on phase II clinical data with ACD440 for neuropathic pain accepted at pain conference
August 9, 2023 AlzeCure publishes the positive clinical results from the phase I trial of NeuroRestore ACD856 against Alzheimer’s
July 11, 2023 AlzeCure publishes new disease modifying data with NeuroRestore ACD856 against Alzheimer’s and cognitive disorders
June 13, 2023 New article on disease modifying data with NeuroRestore ACD856 against Alzheimer’s now available online
April 19, 2023 AlzeCure gets an abstract on non-opioid ACD440 for neuropathic pain accepted at the EFIC 2023 Conference
March 30, 2023 AlzeCure presents new data at Alzheimer’s conference AD/PD on the potential disease-modifying effect of NeuroRestore ACD856
March 28, 2023 AlzeCure presents new data on its preventive treatment Alzstatin at the Alzheimer’s conference AD/PD 2023
March 13, 2023 AlzeCure achieves Last Patient Last Visit (LPLV) in its phase II clinical trial of the non-opioid ACD440 in neuropathic pain
January 31, 2023 Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440
January 11, 2023 AlzeCure selects CD and enters next development phase with Alzstatin ACD680 against Alzheimer’s
December 20, 2022 AlzeCure gets abstract accepted on new potential disease-modifying effects of ACD856 against Alzheimer’s
December 15, 2022 AlzeCure gets late-breaking abstract on new data with its Alzheimer project Alzstatin accepted at AD/PD 2023
December 13, 2022 AlzeCure Pharma AB’s Chief Scientific Officer has participated in an interview with Erik Penser Bank
December 6, 2022 The subscription period in AlzeCure Pharma AB’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank
December 1, 2022 New data on Alzstatin for preventive treatment against Alzheimer’s presented at Alzheimer’s conference CTAD
November 30, 2022 New data strengthening the continued clinical development of NeuroRestore ACD856 presented at Alzheimer’s conference
October 24, 2022 AlzeCure gets abstract accepted on positive clinical EEG results with Alzheimer’s project NeuroRestore ACD856
October 20, 2022 AlzeCure presents new data with its preventive treatment Alzstatin at the Alzheimer conference CTAD
October 18, 2022 AlzeCure gets new abstract accepted on ACD856’s indicative disease-modifying effects against Alzheimer’s
October 11, 2022 New data from AlzeCure demonstrate potential disease-modifying effects of NeuroRestore ACD856
October 6, 2022 AlzeCure presents its project portfolio in Alzheimer’s and pain at Redeye’s theme day on October 12
September 22, 2022 AlzeCure presents new data on the anti-inflammatory effects of its TrkA-NAM pain project at IASP 2022
September 16, 2022 AlzeCure’s Alzheimer’s project NeuroRestore ACD856 shows positive effect on brain activity in clinical trial
August 30, 2022 AlzeCure gets abstract accepted on potential neuroprotective effects of NeuroRestore ACD856
August 16, 2022 New review article on AlzeCure’s NeuroRestore as a novel Alzheimer’s therapy published in Drug Discovery Today
August 2, 2022 AlzeCure presents new clinical data with NeuroRestore ACD856 at the Alzheimer’s conference AAIC
July 5, 2022 AlzeCure gets abstract on new clinical study data with NeuroRestore accepted at the Alzheimer’s conference AAIC
June 21, 2022 First patient included in AlzeCure’s Phase II clinical trial in neuropathic pain with non-opioid ACD440
June 15, 2022 Study plan of AlzeCure’s Phase II clinical study in neuropathic pain with non-opioid ACD440 now available
May 25, 2022 AlzeCure gets approval to start Phase II clinical trial with non-opioid pain project ACD440
May 10, 2022 AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference
March 17, 2022 AlzeCure presents new data at AD/PD meeting on NeuroRestore’s positive effect on mitochondrial function
March 8, 2022 AlzeCure receives positive indicative clinical data with ACD856 in development for Alzheimer’s disease
February 8, 2022 AlzeCure is moving towards Phase IIa clinical trial with ACD440 based on guiding response from the FDA
January 27, 2022 Novel data in Alzstatin Alzheimer’s project presented at the 11th Pharmaceutical Profiling meeting
January 18, 2022 AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conference
January 11, 2022 AlzeCure gets late breaking abstract accepted on NeuroRestore’s positive effect on mitochondrial function
October 6, 2021 AlzeCure Pharma develops novel analgesic drug based on Nobel prize-winning discoveries
October 5, 2021 New data showing the potential of the NeuroRestore project in depression presented at ECNP 2021 conference
October 4, 2021 AlzeCure’s Alzheimer project has initiated the next clinical phase I study with ACD856
August 30, 2021 AlzeCure’s Alzheimer’s project receives approval to start next clinical phase I study with ACD856
August 27, 2021 AlzeCure’s ACD856 demonstrates good tolerability in Phase I clinical trial and is approved for additional doses
August 17, 2021 AlzeCure gives live streamed strategy update on Alzheimer’s disease and NeuroRestore on September 1
August 12, 2021 AlzeCure to present abstract at ECNP conference on NeuroRestore project’s potential in depression
July 29, 2021 New data supporting targeting Trk receptors with ACD856 for treatment of Alzheimer’s disease presented at AAIC 2021
June 11, 2021 New results from AlzeCure’s pain project TrkA-NAM presented at the IASP pain conference
June 10, 2021 Positive clinical data on the novel non-opioid VR1 antagonist ACD440 presented at IASP pain conference
April 27, 2021 AlzeCure gets late-breaking abstract on ACD440 in neuropathic pain accepted for presentation
December 7, 2020 AlzeCure receives approval to start clinical Phase Ib trial with ACD440 in neuropathic pain
